Last reviewed · How we verify
Concurrent chemotherapy
Concurrent chemotherapy administers multiple cytotoxic chemotherapy agents simultaneously or in close temporal proximity to enhance tumor cell death.
Concurrent chemotherapy administers multiple cytotoxic chemotherapy agents simultaneously or in close temporal proximity to enhance tumor cell death. Used for Various solid tumors (specific indication dependent on chemotherapy agents and trial design).
At a glance
| Generic name | Concurrent chemotherapy |
|---|---|
| Also known as | CC, Chemotherapy, albumin-bound paclitaxel, cisplatin |
| Sponsor | Sun Yat-sen University |
| Drug class | Chemotherapy combination regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Concurrent chemotherapy combines two or more chemotherapy drugs given at the same time or overlapping schedules to achieve synergistic cytotoxic effects against cancer cells. This approach may improve response rates compared to sequential or single-agent chemotherapy by targeting multiple pathways of cell division and DNA replication simultaneously. The specific mechanism depends on the chemotherapy agents used and their individual modes of action.
Approved indications
- Various solid tumors (specific indication dependent on chemotherapy agents and trial design)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Mucositis
- Diarrhea
- Alopecia
- Fatigue
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
- Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer (PHASE1)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (PHASE3)
- Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma (PHASE2)
- A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Concurrent chemotherapy CI brief — competitive landscape report
- Concurrent chemotherapy updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI